Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ful-23
- Development stage
- Preclinical
- Lead developer
- Charles Drew University of Medicine & Science
- Modality
- Small Molecules
01
Overview
Ful-23 is a novel small molecule inhibitor of Monocarboxylate Transporter 4 (MCT4) being investigated for the treatment of acute myeloid leukemia (AML). Developed by researchers at Charles Drew University of Medicine & Science, Ful-23 targets the metabolic vulnerabilities of cancer cells by blocking the export of lactate, leading to intracellular lactate accumulation and acidification. This metabolic disruption results in inhibited cell proliferation and the induction of apoptosis. Preclinical studies have demonstrated that Ful-23 exhibits significant synergistic effects when combined with the standard chemotherapeutic agent cytarabine, enhancing antitumor activity in both cell lines and zebrafish models of AML.
Beyond the preview
Go deeper on Ful-23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ful-23.